Bladder tumor in elderly patients with renal impairment bladder tumor
Conditions
Interventions
When performing PDD-TURBT in elderly patients with bladder tumor and renal impairment, the dose of 5-aminolevulinic acid is reduced from 20 mg/kg to 10 mg/kg.
Sponsors
Miyakawa University Jinpei
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with bladder tumor scheduled for PDD-TURBT (2) Patients confirmed to have an eGFR of less than 45 at least once within the last 12 weeks (3) Age: Patients aged 80 years or older at the time of obtaining consent (4) Gender: Both sexes (5) Patients who have received sufficient explanation regarding participation in this study, fully understood the contents, and provided written informed consent of their own free will (6) Patients capable of hospitalization according to the study schedule
Exclusion criteria
Exclusion criteria: (1) Patients with a history of hypersensitivity to 5-aminolevulinic acid or porphyrins (2) Patients with porphyria (3) Patients with a history of hypotension caused by the use of 5-aminolevulinic acid (4) Other patients judged ineligible for participation in this study by the principal investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of composite events (severe hypotension or hepatic impairment) during the perioperative period | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Perioperative hypotension (2) Incidence rate of perioperative hepatic impairment (3) Amount of vasopressors (Phenylephrine, ephedrine) used intraoperatively (4) Sensitivity and specificity of lesion detection compared with white-light TURBT | — |
Contacts
Public ContactJinpei Miyakawa
The University of Tokyo Hospital
Outcome results
None listed